funapide funapide funapide (inn) (former developmental code names tv-45070 and xen402) is a novel analgesic under development by xenon pharmaceuticals (formerly in partnership with teva pharmaceutical industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. it acts as a small-molecule nav1.7 and nav1.8 voltage-gated sodium channel blocker. funapide is being evaluated in humans in both oral and topical formulations, and as of july 2014, has reached phase iib clinical trials. funapideclinical dataroutes ofadministrationby mouth, topicalatc codenoneidentifiers iupac name (7s)-1'-methyl]spirobenzodioxole-7,3'-indole]-2'-one cas number1259933-16-8 ypubchem cid49836093chemspider34500834uniia5595lhj2lkeggd11156chemical and physical dataformulac22h14f3no5molar mass429.351 g·mol−13d model (jsmol)interactive image smiles c1c2(c3=cc=cc=c3n(c2=o)cc4=cc=c(o4)c(f)(f)f)c5=cc6=c(c=c5o1)oco6 inchi inchi=1s/c22h14f3no5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8h,9-11h2/t21-/m0/s1key:nebuoxbynahkfv-nrfanrhfsa-n